News | November 05, 2010

UIC Awarded $12 Million to Study Root Causes of Heart Failure

November 5, 2010 – The National Heart, Lung, and Blood Institute has awarded the University of Illinois at Chicago (UIC) more than $12 million to investigate the acquired and familial causes of heart failure. The goal is to identify markers for diagnosis and targets for cures.

The funding will support an ongoing program-project grant led by R. John Solaro, head of physiology and biophysics at UIC. Solaro’s program links the expertise of several UIC researchers together. Over the program’s 10-year life, dozens of papers have been published in top journals.

"We’re looking at the overarching problem of the maladaptive changes the heart undergoes that lead into a vicious cycle of failure," says Solaro.

His collaborators are Brenda Russell, professor in physiology and biophysics; E. Douglas Lewandowski, professor in physiology and biophysics; and Pieter de Tombe, chair of physiology at Loyola University, Chicago.

Projects led by Solaro and de Tombe investigate energy consumption by the molecular motors of the cardiac muscle, called sarcomeres, which generate the pressure to pump blood through the arteries. Pilot studies have identified possible therapies for common familial cardiac disorders for which there is presently no cure.

Russell addresses the mechanisms for growth of the heart-muscle cells and the assembly of the sarcomeres during growth.

Lewandowski focuses on the metabolic pathways that supply energy to the molecular motors and on the coordination of energy supply and demand. Cellular metabolism is important, he said, because scientists think "the interplay between protein function and expression in the heart, and metabolic processes in the cell, can either make or break the contractile function of the heart."

For more information: www.uic.edu

Related Content

Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init